Physician profile
Mitchell Stashower
NPI 1801894290
$1,117.88
in general payments reported to CMS, 2019-2025
15 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $91.75 · 2021: $144 · 2022: $258 · 2023: $89.01 · 2024: $104 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $490.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $222.38 | 2019-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $159.05 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $141.14 | 2025 | Cabtreo, Jublia, Siliq |
| Almirall LLC | $130.39 | 2019-2025 | Klisyri |
| Leo Pharma INC. | $105.23 | 2022-2025 | Adbry, Anzupgo |
| Incyte Corporation | $95.58 | 2022-2024 | Opzelura |
| Amgen INC. | $53.72 | 2024-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $49.08 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $30.64 | 2022 | |
| Genzyme Corporation | $30.02 | 2022 | |
| Abbvie INC. | $26.37 | 2022 | |
| Pfizer INC. | $23.01 | 2022 | |
| Journey Medical Corporation | $18.94 | 2025 | |
| Dermavant Sciences, INC. | $16.92 | 2023 | Vtama |
| Lilly USA, LLC | $15.41 | 2024 | Taltz, Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Stashower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.